Skip Navigation


JAC Advance Access originally published online on July 24, 2006
Journal of Antimicrobial Chemotherapy 2006 58(3):575-579; doi:10.1093/jac/dkl290
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
58/3/575    most recent
dkl290v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cordeiro, R. d. A.
Right arrow Articles by Sidrim, J. J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cordeiro, R. d. A.
Right arrow Articles by Sidrim, J. J. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

In vitro inhibitory effect of antituberculosis drugs on clinical and environmental strains of Coccidioides posadasii

Rossana de Aguiar Cordeiro1–,3,*, Raimunda Sâmia Nogueira Brilhante1,2, Marcos Fábio Gadelha Rocha1,4, Maria Auxiliadora Bezerra Fechine1, Zoilo Pires de Camargo5 and José Júlio Costa Sidrim1,2

1 Medical Mycology Specialized Center, Federal University of Ceará Fortaleza, Ceará, Brazil 2 Post-graduation Program in Medical Sciences, Federal University of Ceará Fortaleza, Ceará, Brazil 3 Department of Biological Science, State University of Ceará Fortaleza, Ceará, Brazil 4 Post-graduation Program in Veterinary Science, State University of Ceará Fortaleza, Ceará, Brazil 5 Department of Microbiology, Immunology and Parasitology, Federal University of São Paulo São Paulo, Brazil

Received 26 February 2006; returned 12 April 2006; revised 22 May 2006; accepted 23 June 2006

*Corresponding author. Tel: +55-85-214-2853; Fax: +55-85-295-1736; E-mail: ross{at}uece.br

Objectives: The aim of the present study was to evaluate the in vitro effect of the first-line antimicrobial drugs for pulmonary tuberculosis against the fungal pathogen Coccidioides posadasii.

Methods: The in vitro activities of rifampicin, isoniazid, pyrazinamide and ethambutol against clinical and environmental strains of C. posadasii were determined in accordance with the CSLI M38-A macrodilution method. The antimicrobials were tested alone or in combinations of two or more drugs.

Results: With the exception of pyrazinamide, all of the tested drugs interfered with the in vitro growth of C. posadasii. The 2 day MIC ranges of the tested drugs were as follows: rifampicin 1060–4250 mg/L; isoniazid ≤250 mg/L; ethambutol ≤620 mg/L. Pronounced in vitro synergism was demonstrated for combined antituberculosis drugs. The combination of rifampicin plus pyrazinamide was the only one that did not inhibit fungal growth.

Conclusions: The present study showed that the first-line antituberculosis drugs, alone or in combinations, interfered with the vegetative growth of C. posadasii strains in vitro. Further studies in a murine model will need to be conducted in order to evaluate the in vivo effect of antituberculosis drugs on Coccidioides spp.

Keywords: susceptibility testing , coccidioidomycosis , pulmonary tuberculosis , Brazil


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.